Faraday Future Celebrates Major Milestone in its Middle East 'Third Pole' Strategy with its New Operations Facility Handover Ceremony in Ras Al Khaimah, UAE
RAS AL KHAIMAH, United Arab Emirates--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) ('Faraday Future', 'FF' or 'Company'), a California-based global shared intelligent electric mobility ecosystem company, announced that it held a formal handover ceremony for its first regional facility in Ras Al Khaimah, United Arab Emirates, marking a significant milestone in the execution of its Middle East 'Third Pole' strategy, alongside the dual-home market strategy in U.S. and China. The project was formally announced on May 21, 2025, during RAKEZ's participation in Make it in the Emirates 2025 in Abu Dhabi, where a lease agreement was signed between RAKEZ and Faraday Future Middle East FZ-LLC, the subsidiary of FF.
The 108,000-square-foot facility will encompass an office, engineering workshop, and operational hub. The facility will support both the FF brand and potential FX models, serving as a hub for operations across the GCC, with potential future expansion into Europe and North Africa.
The handover ceremony event, held at the site of the facility in the Al Hamra area of the Ras Al Khaimah Economic Zone (RAKEZ), signifies FF's official landing in the Middle East and a major step in the Company's strategic global expansion. The ceremony was attended by Faraday Future's Global Co-CEO Matthias Aydt, Chief Financial Officer Koti Meka, Head of Middle East and Executive Director Chui Tin Mok, and Ramy Jallad, Group CEO of RAKEZ, highlighting the significance of this project for both FF and the region.
'This handover event represents a tangible start for both FF and FX in the region,' said Matthias Aydt, Global Co-CEO of Faraday Future. 'Ras Al Khaimah offers the right infrastructure, visionary leadership, and regional connectivity to support our goal of building an intelligent, sustainable mobility ecosystem. We are proud to build a facility that will not only serve as a gateway to the region but also has the potential to create up to 200 skilled jobs.'
RAKEZ played a critical role in enabling FF's smooth entry into the UAE, offering comprehensive support from infrastructure and permitting, to regulatory alignment.
'Faraday Future's entry is more than the launch of a facility—it marks the beginning of a bold new chapter in the region's mobility landscape,' said Ramy Jallad, Group CEO of RAKEZ. 'As the UAE accelerates toward its green mobility goals, FF's vision and presence in Ras Al Khaimah perfectly align with national ambitions for a sustainable, electric future.'
Operations at the new site are expected to commence in the second half of 2025. In the longer term, FF aims to establish regional R&D capabilities, and a localized supply chain anchored in Ras Al Khaimah, reinforcing its vision of sustainable, AI-powered mobility.
ABOUT FARADAY FUTURE
Faraday Future is a California-based global shared intelligent electric mobility ecosystem company. Founded in 2014, the Company's mission is to disrupt the automotive industry by creating a user-centric, technology-first, and smart driving experience. Faraday Future's flagship model, the FF91, exemplifies its vision for luxury, innovation, and performance. The FX strategy aims to introduce mass production models equipped with state-of-the-art luxury technology similar to the FF 91, targeting a broader market with middle-to-low price range offerings. FF is committed to redefining mobility through AI innovation. Join us in shaping the future of intelligent transportation. For more information, please visit https://www.ff.com/us/.
FORWARD LOOKING STATEMENTS
This release includes 'forward looking statements' within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this release the words 'plans,' 'vision,' 'will,' 'future,' 'expected' and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements, which include statements regarding the Company's Middle East strategy, including establishing operational, sales and production activities in the region, creating jobs in the UAE region, expanding to Europe and North Africa, and potential FX models involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, which could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include, among others: the Company's ability to secure the necessary funding to execute on the FX strategy and the UAE strategy, which will be substantial; the ability of the Company to execute across multiple concurrent strategies, including the UAE, bridge strategy, FX, EREV, AI, and US geographic expansion; the Company's ability to secure necessary agreements to license or produce FX vehicles in the Middle East or elsewhere, none of which have been secured; the Company's ability to homologate FX vehicles for sale in the Middle East or elsewhere, as necessary; the potential impacts of changing tariff policies; the Company's ability to continue as a going concern and improve its liquidity and financial position; the Company's ability to pay its outstanding obligations; the Company's ability to remediate its material weaknesses in internal control over financial reporting and the risks related to the restatement of previously issued consolidated financial statements; the Company's limited operating history and the significant barriers to growth it faces; the Company's history of losses and expectation of continued losses; the success of the Company's payroll expense reduction plan; the Company's ability to execute on its plans to develop and market its vehicles and the timing of these development programs; the Company's estimates of the size of the markets for its vehicles and cost to bring those vehicles to market; the rate and degree of market acceptance of the Company's vehicles; the Company's ability to cover future warranty claims; the success of other competing manufacturers; the performance and security of the Company's vehicles; current and potential litigation involving the Company; the Company's ability to receive funds from, satisfy the conditions precedent of and close on the various financings described elsewhere by the Company; the result of future financing efforts, the failure of any of which could result in the Company seeking protection under the Bankruptcy Code; the Company's indebtedness; the Company's ability to cover future warranty claims; the Company's ability to use its 'at-the-market' program; insurance coverage; general economic and market conditions impacting demand for the Company's products; potential negative impacts of a reverse stock split; potential cost, headcount and salary reduction actions may not be sufficient or may not achieve their expected results; circumstances outside of the Company's control, such as natural disasters, climate change, health epidemics and pandemics, terrorist attacks, and civil unrest; risks related to the Company's operations in China; the success of the Company's remedial measures taken in response to the Special Committee findings; the Company's dependence on its suppliers and contract manufacturer; the Company's ability to develop and protect its technologies; the Company's ability to protect against cybersecurity risks; and the ability of the Company to attract and retain employees, any adverse developments in existing legal proceedings or the initiation of new legal proceedings, and volatility of the Company's stock price. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the 'Risk Factors' section of the Company's Form 10-K filed with the SEC on March 31, 2025, and other documents filed by the Company from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of the 10 biotech stocks screaming a buy. On June 17, the company moved to attract and retain top talent by granting inducement awards to 41 employees. Under the 2024 Inducement Plan, the company will award the employees non-qualified stock options of 187,664 shares and 89.582 restricted stock units designed to attract and retain talent. A pharmacist in a pharmacy preparing a prescription medication for a patient suffering from Fibromyalgia. The move to offer inducement awards is part of Acadia Pharmaceuticals' push to secure top-skilled professionals essential for its neuroscience projects. It expects the awards to ensure employees are incentivized to contribute to the long-term objectives expected to lead to sustained growth and innovation. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharma company dedicated to advancing treatments for central nervous system disorders and rare diseases. Its key products include NUPLAZID, approved for Parkinson's disease psychosis, and DAYBUE. While we acknowledge the potential of ACAD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
36 minutes ago
- Yahoo
Wolfe Research Initiates Coverage of BridgeBio Pharma (BBIO) with ‘Outperform' Rating
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 10 biotech stocks screaming a buy. On June 17, Wolfe Research initiated coverage of the stock with an 'Outperform' rating and a $49 price target. The research firm reiterated the company's solid position amid the 'TTR craze' while also echoing its commercial execution strategy. A medical technician wearing a lab coat operating machinery in a biopharmaceutical laboratory. Consequently, Wolfe Research expects BridegBio's revenue to total $569 million in 2025 before rising to $3.4 billion by 2028. It should peak at $4.4 billion in 2034. For the upcoming second quarter, the research firm expects the company to deliver revenue of $106 million, slightly below market expectation of $111 million. While the stock has shown a remarkable return of 42% year to date, Wolfe Research insists it must navigate several challenges to maintain the positive momentum. It must navigate the potential Vyndaqel loss of exclusivity, achondroplasia data versus competition, and pipeline products. In addition, consistent revenue growth and expanding operating margins will be crucial to the company's long-term success. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biopharmaceutical company that develops and delivers transformative medicines for genetic diseases. Its pipeline includes a range of development programs, from early science to advanced clinical trials. While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Sign in to access your portfolio
Yahoo
36 minutes ago
- Yahoo
Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 10 biotech stocks screaming a buy. On June 12, the company announced the upcoming retirement of Richard Geary, Ph.D., its executive vice president and chief development officer, effective January 2026. Holly Kordasiewicz, Ph.D., currently senior vice president of neurology, will take over the role. Geary has been with Ionis since 1995 and played a pivotal role in bringing six medicines to regulatory approval, including the company's first independently commercialized drug, TRYNGOLZA. A biotechnologist pouring liquid into a test tube and analyzing its components in a lab. Dr. Kordasiewicz, who joined Ionis in 2011, brings over 20 years of experience in R&D, particularly in neurology. She leads the company's neurology program, covering treatments for conditions such as Alzheimer's disease, Angelman syndrome, and Alexander disease. Her work has also contributed to key partnered programs with Biogen, including the development of QALSODY® and IONIS-MAPTRx. As Dr. Geary transitions out of his role, he will continue as a strategic consultant through 2026 to ensure continuity. Ionis leadership praised both Geary's legacy and Kordasiewicz's appointment as a pivotal step in driving the company's commitment to developing transformational therapies for patients with serious diseases. Ionis Pharmaceuticals, Inc. is a U.S.-based commercial-stage biotech company specializing in RNA-targeted therapies. Its approved products include TRYNGOLZA for FCS, WAINUA, and TEGSEDI for ATTRv-PN, SPINRAZA for spinal muscular atrophy, QALSODY for ALS, and WAYLIVRA for rare lipid disorders. The company has a robust pipeline, including late-stage programs like Olezarsen (for hypertriglyceridemia), Donidalorsen (for hereditary angioedema), and Zilganerse (for Alexander disease), along with several mid-stage treatments for neurological and metabolic conditions. Ionis also collaborates with leading pharma firms, including Biogen, GSK, AstraZeneca, Novartis, Roche, and Metagenomi, expanding its reach in developing transformative RNA therapies. While we acknowledge the potential of IONS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None.
